[P4, a new substance for the treatment of Parkinson syndrome. Initial results of a clinical trial].
In fourteen patients with a pronounced Parkinson syndrome of cerebral atherosclerotic or dostencephalitic genesis, good to very good success can be achieved with an average dosage of 3--4 tablets, three times a day (=45--60 mg) of the test substance, which is a bencilic acid ester preparation. The tremor, hypokinesis, and the psychic syndrome were particularly favourably affected. This success was also achieved in clinical pictures which had already lasted more than ten years.
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001561:Benzilates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*
D000978:Antiparkinson Agents; D001561:Benzilates
P4, eine neue Substanz zur Behandlung des Parkinsonsyndroms. Vorläufige Ergebnisse einer klinischen Erprobung.